Naomi B. Haas

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 27 papers. Top paper: “Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study”.

Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study

The Lancet Oncology(2024)10.1016/s1470-2045(24)00211-0

N/A

1.9DataRank · unranked

86 citations

Se-Eun Kim, Viraj A. Master, David H. McDermott, Lauren C. Harshman, Suzanne Cole +40 more

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)00913-3

N/A

1.4DataRank · unranked

49 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +14 more

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810

Journal of Clinical Oncology(2024)10.1200/jco.23.01544

N/A

0.930DataRank · unranked

19 citations

Se Eun Kim, Wayne Harris, Sumanta K. Pal, Michael R. Pins, Jill Kolesar +13 more

Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7047

N/A

0.421DataRank · unranked

11 citations

Tao Liu, Xue Song, Joshua D. Mitchell, JoRean D. Sicks, Ilana F. Gareen +10 more

PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5101

N/A

0.330DataRank · unranked

8 citations

Mäneka Puligandla, Mohamad E. Allaf, David F. McDermott, Charles G. Drake, Sabina Signoretti +15 more

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

Cancer Medicine(2021)10.1002/cam4.4140

N/A

0.315DataRank · unranked

5 citations

Hannah Fullington, David E. Gerber, I. Alex Bowman, Mäneka Puligandla, Janice P. Dutcher +3 more

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical Genitourinary Cancer(2023)10.1016/j.clgc.2023.06.012

N/A

0.261DataRank · unranked

4 citations

Se Eun Kim, David F. McDermott, Janice P. Dutcher, Mäneka Puligandla, Judith Manola +10 more

Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805

Journal of the National Comprehensive Cancer Network(2023)10.6004/jnccn.2023.7018

N/A

0.203DataRank · unranked

2 citations

Yael Flamand, Naomi B. Haas, Anne O’Neill, Robert S. DiPaola, Pearl Subramanian +6 more

EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.17_suppl.lba4500

N/A

0DataRank · unranked

39 citations

Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva +15 more

Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.342

N/A

0DataRank · unranked

0 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert Guy Uzzo +5 more

Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.270

N/A

0DataRank · unranked

9 citations

Catherine M. Tangen, Ian M. Thompson, Naomi B. Haas, Daniel J. George, Daniel Yick Chin Heng +15 more

Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.10.016

N/A

0DataRank · unranked

12 citations

Caleb Hearn, Emily Getzen, Qi Long, David C. Lee, Tony M. Keaveny +14 more

Triplet Strategies in Metastatic Clear Cell Renal Cell Carcinoma: A Worthy Option in the First-Line Setting?

American Society of Clinical Oncology Educational Book(2023)10.1200/edbk_389650

N/A

0DataRank · unranked

9 citations

Jeffrey Shevach, Ronan Flippot, Laurence Albigès, Naomi B. Haas, Kathryn E. Beckermann +1 more

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4596

N/A

0DataRank · unranked

10 citations

Se Eun Kim, Viraj A. Master, David F. McDermott, Sabina Signoretti, David Cella +15 more

Localised non‐metastatic sarcomatoid renal cell carcinoma: a 31‐year externally verified study

British Journal of Urology(2023)10.1111/bju.16125

N/A

0DataRank · unranked

7 citations

Andrew W. Silagy, Andrea Knežević, Stanley Weng, Alan Wang, Roy Mano +13 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4541

N/A

0DataRank · unranked

1 citations

Se Eun Kim, David F. McDermott, Viraj A. Master, Sabina Signoretti, Mahmut Akgül +13 more

Data from Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial

(2023)10.1158/1078-0432.c.6517693.v1

N/A

0DataRank · unranked

0 citations

Gina R. Petroni, Walter C. Olson, Mark E. Smolkin, Merrick I. Ross, Naomi B. Haas +5 more

Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

(2023)10.1158/1078-0432.c.6532368.v1

N/A

0DataRank · unranked

0 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0025

N/A

0DataRank · unranked

46 citations

Mäneka Puligandla, Brian Halbert, Naomi B. Haas, Keith T. Flaherty, Robert G. Uzzo +5 more

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

UNC Libraries(2020)10.17615/yxdm-6w50

N/A

0DataRank · unranked

0 citations

Christopher J. Sweeney, Frauke Schimmöller, Dana E. Rathkopf, Naomi B. Haas, Celestia S. Higano +16 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

European Urology(2024)10.1016/j.eururo.2024.05.012

N/A

0DataRank · unranked

8 citations

Catherine M. Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell V. Meng +16 more

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma

Cancer Discovery(2025)10.1158/2159-8290.cd-24-0991

N/A

0DataRank · unranked

38 citations

Lena V. Wirth, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more

Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma

The Oncologist(2025)10.1093/oncolo/oyaf138

N/A

0DataRank · unranked

0 citations

Neil J. Shah, Matthew T. Campbell, Naomi B. Haas, Ariel Ann Nelson, Moshe Chaim Ornstein +12 more

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2972

N/A

0DataRank · unranked

58 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574

The Journal of Immunology(2025)10.1093/jimmun/vkaf283.1362

N/A

0DataRank · unranked

0 citations

Miya B. Hugaboom, Kelly Street, Neil Ruthen, Opeyemi A. Jegede, Nicholas R. Schindler +22 more